CCM
Cutter Capital Management Portfolio holdings
AUM
$230M
This Quarter Return
+2.37%
1 Year Return
+11.51%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$230M
AUM Growth
+$230M
(-5.9%)
Cap. Flow
-$16.9M
Cap. Flow
% of AUM
-7.37%
Top 10 Holdings %
Top 10 Hldgs %
62.84%
Holding
31
New
10
Increased
5
Reduced
6
Closed
10
Top Buys
| 1 |
Bristol-Myers Squibb
BMY
|
$18M |
| 2 |
Biogen
BIIB
|
$15.5M |
| 3 |
Eli Lilly
LLY
|
$14.9M |
| 4 |
Roivant Sciences
ROIV
|
$13.1M |
| 5 |
VRNA
Verona Pharma
VRNA
|
$10.2M |
Top Sells
| 1 |
Regeneron Pharmaceuticals
REGN
|
$22.4M |
| 2 |
Johnson & Johnson
JNJ
|
$20.5M |
| 3 |
AbbVie
ABBV
|
$18.1M |
| 4 |
Sarepta Therapeutics
SRPT
|
$15.1M |
| 5 |
Royalty Pharma
RPRX
|
$12.7M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Bristol-Myers Squibb
BMY
$96B
| $18M | 7.83% |
+295,000
| New | +$18M |
|
2
Amgen
AMGN
$155B
| $15.6M | 6.78% |
50,000
+11,910
| +31% | +$3.71M |
|
|
3
Biogen
BIIB
$19.4B
| $15.5M | 6.76% |
+113,500
| New | +$15.5M |
|
|
4
Eli Lilly
LLY
$657B
| $14.9M | 6.47% |
+18,000
| New | +$14.9M |
|
5
Insmed
INSM
$28.8B
| $14.2M | 6.19% |
186,384
-24,500
| -12% | -$1.87M |
|
6
Ultragenyx Pharmaceutical
RARE
$2.89B
| $13.7M | 5.98% |
379,303
-27,500
| -7% | -$996K |
|
7
BridgeBio Pharma
BBIO
$9.89B
| $13.5M | 5.88% |
390,644
-169,700
| -30% | -$5.87M |
|
8
Perrigo
PRGO
$3.27B
| $13.4M | 5.85% |
479,517
+185,000
| +63% | +$5.19M |
|
|
9
Roivant Sciences
ROIV
$8.15B
| $13.1M | 5.71% |
+1,300,000
| New | +$13.1M |
|
10
Teva Pharmaceuticals
TEVA
$21.1B
| $12.3M | 5.37% |
801,806
+216,923
| +37% | +$3.33M |
|
|
11
Royalty Pharma
RPRX
$15.6B
| $11.1M | 4.84% |
356,894
-407,965
| -53% | -$12.7M |
|
12
Tarsus Pharmaceuticals
TARS
$2.47B
| $10.5M | 4.59% |
205,000
+92,500
| +82% | +$4.75M |
|
|
VRNA
13
Verona Pharma
VRNA
$9.16B
| $10.2M | 4.42% |
+160,000
| New | +$10.2M |
|
14
Madrigal Pharmaceuticals
MDGL
$9.76B
| $7.95M | 3.46% |
+24,000
| New | +$7.95M |
|
15
Summit Therapeutics
SMMT
$17.6B
| $7.72M | 3.36% |
+400,000
| New | +$7.72M |
|
16
Halozyme
HALO
$8.56B
| $7.66M | 3.33% |
+120,000
| New | +$7.66M |
|
17
Cytokinetics
CYTK
$4.23B
| $7.03M | 3.06% |
+175,000
| New | +$7.03M |
|
18
Agios Pharmaceuticals
AGIO
$2.19B
| $6.9M | 3% |
235,350
-66,273
| -22% | -$1.94M |
|
|
CNTA
19
Centessa Pharmaceuticals
CNTA
$2.25B
| $6.01M | 2.62% |
418,127
+271,051
| +184% | +$3.9M |
|
20
Arcus Biosciences
RCUS
$1.13B
| $5.74M | 2.5% |
+731,818
| New | +$5.74M |
|
21
NewAmsterdam Pharma
NAMS
$2.71B
| $4.53M | 1.97% |
221,152
-116,000
| -34% | -$2.37M |
|
|
22
AbbVie
ABBV
$372B
| – | – |
-101,996
| Closed | -$18.1M |
|
23
Akero Therapeutics
AKRO
$3.74B
| – | – |
-230,000
| Closed | -$6.4M |
|
24
Janux Therapeutics
JANX
$1.37B
| – | – |
-120,000
| Closed | -$6.42M |
|
|
25
Johnson & Johnson
JNJ
$427B
| – | – |
-141,572
| Closed | -$20.5M |
|